Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials.

Author information

Affiliations

  • 1. Department of Biochemistry, Tarbiat Modares University, 14115-175 Tehran, Iran.
      Authors
    • Akhbariyoon H 1
    • Azizpour Y 1
    • Esfahani MF 1
    (3 authors)
  • 2. Department of Biology, Faculty of Science, Yazd University, Yazd, Iran.
      Authors
    • Firoozabad MSM 2
    • Esfahani KS 2
    • Khoshavi N 2
    • Karimi N 2
    • Shirinisaz A 2
    • Abedi F 2
    • Rad MR 2
    • Sharifi P 2
    (8 authors)
  • 3. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
      Authors
    • Rad MR 3
    (1 author)

Clinical Immunology (Orlando, Fla.), 21 Oct 2021, 232:108873
https://doi.org/10.1016/j.clim.2021.108873 PMID: 34688855 

Review

Abstract 

Advances in Cancer immunotherapy in the past few years include the development of medications that modulate immune checkpoint proteins. Cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death protein 1 (PD1), and programmed cell death ligand 1 (PD-L1) are three co-inhibitory receptors that are expressed in the tumor microenvironment. Immune checkpoint inhibitors (ICI) that target these biomarkers unleash the properties of effector T cells that are licensed to kill cancer cells. Immune checkpoint blockade has dramatically changed the treatment landscape of many cancers. In this Review, we describe the current data regarding clinical trials of ICIs in six important cancers, including hepatocellular carcinoma (HCC), renal cell cancer (RCC), hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), non-small cell lung cancer (NSCLC), and head and neck cancer carcinoma (HNSCC).

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.clim.2021.108873

Citations & impact 

Impact metrics

15
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/115744931
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/115744931

Smart citations by scite.ai
Smart citations by scite.ai include citation statements extracted from the full text of the citing article. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1016/j.clim.2021.108873

Supporting
Mentioning
Contrasting
0
18
0

Article citations

Go to all (15) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.